| 摘要 |
PROBLEM TO BE SOLVED: To provide inhibitors for the treatment and/or prophylaxis of diseases which are the consequence of increased receptor tyrosine kinase activity, particularly cancer.SOLUTION: In particular, an altered activity change of receptor tyrosine kinase can be triggered by a mutation of FGFR-4, wherein the mutation is in particular a point mutation in the transmembrane domain of FGFR-4 and leads to an exchange of a hydrophobic amino acid to a hydrophilic amino acid. The invention further concerns the use of an inhibitor directed against FGFR-4, for the treatment and/or prophylaxis of cancer. Furthermore, the invention concerns a mutated FGFR-4, which leads to overexpression and/or altered activity in cells. Finally, the invention concerns a DNA and RNA sequence of a mutated FGFR-4 molecule, a pharmaceutical composition containing the inhibitor, and a diagnostic and screening procedure. |
